A large-scale analysis study on the clinical and viral characteristics of hepatitis B infection with concurrence of hepatitis B surface or E antigens and their corresponding antibodies

Y. Xiang*, P. Chen*, J.R Xia and L.P. Zhang

Department of Laboratory Medicine,
The First Affiliated Hospital of Chongqing Medical University,
Yuzhong District, Chongqing, China

*These authors contributed equally to this study.
Corresponding author: L.P. Zhang
E-mail: 8051226@163.com

Genet. Mol. Res. 16 (1): gmr16019102
Received August 29, 2016
Accepted December 6, 2016
Published February 23, 2017
DOI http://dx.doi.org/10.4238/gmr16019102

Copyright © 2017 The Authors. This is an open-access article distributed under the terms of the Creative Commons Attribution ShareAlike (CC BY-SA) 4.0 License.

ABSTRACT. Concurrent detection of hepatitis B surface antigen (HBsAg) and anti-HBs antibody or hepatitis B surface E antigen (HBeAg) and anti-HBe antibody in patients with chronic hepatitis B (CHB) infection is well established. However, the clinical implications of these proteins remain largely unknown. In this study, demographic, clinical, and laboratory data from 124,865 patients with chronic CHB infection were analyzed. Viral genotypes were determined by nested polymerase chain reaction. A chemiluminescent assay was applied to measure HBsAg, HBsAb, HBeAg, HBeAb, and HBcAb in sera. Among 124,865 patients with CHB infection, 324 (0.3%) were concurrently positive for HBsAg and anti-HBs, and 206 (0.2%) were concurrently positive for HBeAg and anti-HBe. The HBeAg+/anti-HBe+ group was composed of younger patients (P < 0.05). Subgenotype B2 was prevalent in HBV patients concurrently positive for HBeAg and anti-HBe, while
HBV patients positive for both HBsAg and anti-HBs exhibited the C2 subgenotype. Among 530 concurrent patients, 126 (39%) HBsAg+/anti-HBs+ patients were in the low-replication phase, and 62 (19%) were in the reactivation phase; 87 (42%) HBeAg+/anti-HBe+, and 19 (6%) HBsAg+/anti-HBs+ patients were in the immune clearance phase. In this large-scale analysis, the clinical and viral characteristics of HBV infections with concurrent HBsAg/antibody or HBeAg/antibody presentations have been examined, and the results may contribute to the diagnosis and treatment of CHB patients.

**Key words**: Hepatitis B surface antigen; Chronic hepatitis B; Hepatitis B virus; Hepatitis E virus

**INTRODUCTION**

The prevalence of Hepatitis B virus (HBV) and Hepatitis E virus (HEV) is high in China. However, the sero-prevalence of HEV shows an unbalanced distribution among different geographical locations and economic development levels (Jia et al., 2014). HBV infection is the primary cause of chronic hepatitis B (CHB) infection, cirrhosis, and hepatocellular carcinoma (HCC) (Kao and Chen, 2002). Most cases of HCC are associated with cirrhosis, as well as chronic hepatitis B or C viral infections (El-Serag, 2012). CHB infection is considered endemic in China with a carrier rate of 8-20% in the general population. Approximately 130 million people are carriers for the hepatitis B surface antigen (HBsAg) (Luo et al., 1996). Anti-HBs antibodies are the major protective components of vaccine-induced immunity. The majority of people with “resolved” HBV infections harbor the virus intra-hepatically. However, viral replication is controlled by cytotoxic T lymphocytes, and spread is blocked by neutralizing anti-HBs antibodies in the host system. In view of their important protective roles, the presence of anti-HBs antibodies in HBsAg-positive patients with CHB infection is extremely puzzling.

Hepatitis B surface E antigen (HBeAg) is an antigen that can be found between the nucleocapsid core and the lipid envelope. Its correlation with HBV replication is commonly used as a serological marker of CHB infection. When HBeAg disappears, anti-HBe antibodies become detectable. However, in clinical practice, some CHB patients show concurrent HBeAg and anti-Hbe positivity (Liaw, 2009; McMahon, 2009). A previous study has shown that 169 chronic patients (169/1624,10.4%) had concurrent HBeAg and anti-HBe positivity, which was associated with intermediate age and HBV-DNA load, higher alanine aminotransferase level, and more pronounced liver damage as compared with HBeAg-positive or anti-HBe-positive patients alone (Wang et al., 2011).

The aim of this study was to investigate the clinical and viral characteristics of HBV, and to explore the potential mechanisms involved in the concurrent presence of HBeAg/anti-HBe or HBsAg/anti-HBs in CHB infections.

**MATERIAL AND METHODS**

**Patients**

A total of 124,865 patients with CHB infection were recruited from the First Affiliated
Hospital of Chongqing Medical University (Chongqing, China). All subjects provided written informed consent prior to being enrolled in this study. All patients fulfilled the following criteria: 1) diagnosed with CHB infection according to the Chinese consensus criteria (Chinese Society of Hepatology, Chinese Medical Association, Chinese Society of Infectious Diseases, Chinese Medical Association, 2007), and 2) persistent or intermittent elevation of serum alanine aminotransferase (ALT) levels within 12 months before enrollment. All patients with former anti-virus therapy, co-infection with hepatitis C, hepatitis D, or HIV were excluded from the study. The study protocol was approved and carried out in accordance with the guidelines of the Ethics Committee of Chongqing Medical University.

To examine the interplay between the virus and host, CHB patients were grouped according to the four dynamic phases of CHB infection (Liaw, 2009; McMahon, 2009). CHB patients with positive HBeAg, HBV DNA $> 2 \times 10^7$, and normal ALT level were classified into the immune tolerance (IT) group; patients with positive HBeAg, HBV DNA $> 2 \times 10^4$, and elevated ALT levels were classified into the immune clearance (IC) group; patients with negative HBeAg, HBV DNA $< 2 \times 10^3$, and normal ALT levels were included in the low replicative (LR) group; patients with negative HBeAg, HBV DNA $> 2 \times 10^4$, and elevated ALT levels were included in the reactivation (RE) group.

Detection of HBsAg, anti-HBs, HBeAg and anti-HBe

Chemiluminescent microparticle immune assays (Abbott Diagnostics, Irving, TX, USA) were employed to quantify serum levels of HBsAg, anti-HBs, HBeAg, and anti-HBe. A serum HBsAg level of $> 0.05$ IU/mL, anti-HBs $> 10$ mIU/mL, HBeAg titer $> 1.0$ signal to cutoff ratio (S/CO), an anti-HBe titer $< 1.0$ S/CO was regarded as positive. The limitations of the chemiluminescent assay used for antibody/antigen detection was as follows: 1) for HBsAg, precision for reactive specimens (S/CO ≥ 1.000) was ≤ 10%, total specificity and total sensitivity were 99.87 and 99.52%, respectively; 2) for anti-HBs, precision for reactive specimens (S/CO ≥ 1.000) was ≤ 10%, total specificity and total sensitivity were 99.67 and 97.54%, respectively; 3) for HBeAg, precision for reactive specimens (S/CO ≥ 1.000) was ≤ 10%. The specificity for random blood donor and hospitalized patient specimens were ≥ 99.5 and > 99.0%, respectively. The sensitivity was ≥ 99.5%; 4) for anti-HBe, precision for reactive specimens (S/CO ≥ 1.000) was ≤ 10%. The specificity for random blood donor and hospitalized patient specimens were ≥ 99.5 and > 99.0%, respectively. The sensitivity was ≥ 99.5%.

HBV DNA extraction, quantitation, direct sequencing, and genotyping

HBV DNA loads were quantified by real-time polymerase chain reaction (PCR). DNA was extracted from 100 μL serum using the QIAamp DNA Mini kit (Qiagen Inc., Hilden, Germany) according to manufacturer’s recommendations. The lower detection limit of this assay was $10^3$ IU of HBV DNA /mL.

Molecular genotyping for genotypes A-D and subgenotypes B1, B2, C1, and C2 were performed according to the nested PCR methods established by Jin et al. (2008).

Routine tests

The serum levels of ALT and AST were detected using an automatic biochemistry
analyzer (Roche Diagnostics, Rotkreuz, Switzerland). Liver histology was independently assessed by two pathologists according to the Scheuer scoring system.

**Statistical analysis**

Continuous variables are presented as means ± SD, while categorical variables are presented as frequency (percentage). For between-group comparisons, Student's t-test was used for continuous variables, and the chi-square test was used for categorical data. Comparisons between different groups were carried out using analysis of variance. All P values were based on a two-sided test of statistical significance. Significance was accepted at P < 0.05. All analyses were performed using the SPSS software for Windows, version 13.0 (IBM-SPSS, Inc., Chicago, IL, USA).

**RESULTS**

**Demographic and clinical characteristics of CHB patients**

A total of 124,865 CHB patients fulfilled the study criteria, including 324 patients (0.3%) concurrently positive for HBsAg and anti-HBs, and 206 patients (0.2%) concurrently positive for HBeAg and anti-HBe. The demographic, clinical, and serological characteristics of the study participants are shown in Table 1. Patients in the HBeAg+/anti-HBe+ group were found to be significantly younger as compared to the other groups (P < 0.05). Subgenotype B2 (137, 66.7%) was prevalent in CHB patients concurrently positive for HBeAg and anti-HBe, and subgenotype C2 (108, 33.3%) was predominantly found in chronic hepatitis B patients who were positive for both HBsAg and anti-HBs (P < 0.05). There were no significant difference in the sex, ALT, AST, and HBV DNA level between the HBsAg+/anti-HBs+ and the HBeAg+/anti-HBe+ groups.

<table>
<thead>
<tr>
<th>Table 1. Demographic and clinical characteristics of CHB patients concurrently positive for HBsAg+/anti-HBs+ and HBeAg+/anti-HBe+.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total N (%)</td>
</tr>
<tr>
<td>Age (year)</td>
</tr>
<tr>
<td>Male, N (%)</td>
</tr>
<tr>
<td>Female, N (%)</td>
</tr>
<tr>
<td>ALT, U/L</td>
</tr>
<tr>
<td>AST, U/L</td>
</tr>
<tr>
<td>HBV DNA, (copies/mL)</td>
</tr>
<tr>
<td>Genotypes</td>
</tr>
<tr>
<td>B2, N (%)</td>
</tr>
<tr>
<td>C2, N (%)</td>
</tr>
<tr>
<td>Undetected, N (%)</td>
</tr>
</tbody>
</table>

**Natural courses of CHB patients**

Of the 530 concurrent patients, 126 (39%) with double positivity for HBsAg and anti-HBs were in the low-replication phase of the disease, and 62 (19%) were in the reactivation phase. Out of the 87 patients (42%) positive for HBeAg and anti-HBe, 19 (6%) were in the immune clearance phase. None of the concurrent patients were in the IT (immune tolerance) group. All HBeAg+/anti-HBe+ and HBsAg+/anti-HBs+ patients were in the immune clearance phase.
HBV infection with concurrence of markers

Of the 206 patients positive for both HBeAg and anti-HBe, most were categorized into the IC group. Of the 324 patients with HBsAg and anti-HBs positivity, most were in the LR phase of the CHB infection (Table 2).

| Table 2. Distribution of natural disease courses in patients with CHB infection. |
|-----------------|-----------------|-----------------|-----------------|
|                 | IT group N (%)  | IC group N (%)  | LR group N (%)  | RE group N (%)  |
| HBeAg+/anti-HBe+ (N = 206) | 0 (0%)        | 87 (42%)        | 0 (0%)          | 0 (0%)          |
| HBsAg+/anti-HBs+ (N = 324)  | 0 (0%)        | 19 (6%)         | 126 (39%)       | 62 (19%)        |

IT = immune tolerance; IC = immune clearance; LR = low replicative; RE = reactivation.

DISCUSSION

The coexistence of HBsAg and anti-HBs in patients with CHB infection has been reported (Lada et al., 2006; Huang et al., 2010). Theoretically, the concurrence of HBsAg and anti-HBs occurs regularly during the recovery period of acute HBV infections. However, there may be other factors that can lead to coexistence of HBsAgs and anti-HBs. This may include CHB carriage with ineffective anti-HBs responses, breakthrough of HBV in vaccinated individuals, and HBV reactivation in immune patients who underwent immunosuppression therapies (Yu et al., 2005). Of the 124,865 CHB patients in this study, 324 (0.3%) were concurrently positive for HBsAg and anti-HBs, of whom 62 (19%) were in the reactivation phase of the disease. Further genotyping assays demonstrated that subgenotype C2 (108, 33.3%) was predominantly expressed in CHB patients positive for both HBsAg and anti-HBs.

It has been reported that genotype C is the predominant HBV strains in Chinese HBsAg+/anti-HBs+ patients (Liu et al., 2012). Moreover, the presence of genotype C has been suggested as an independent predictive factor of elevated ALT, which corresponds to liver damage and HBV reactivation (Chu and Liaw, 2007a). Some studies have also demonstrated that Chinese patients with genotype C were at a greater risk for HCC (Chan et al., 2004; Yu et al., 2005). It has been suggested that the coexistence of HBsAg and anti-HBs may be a mixed infection response and a monoclonal response to a single epitope (Margeridon et al., 2005). Other studies suggested that amino acid substitutions may decrease or abolish the binding of anti-HBs to HBsAg, leading to immune escape (Mesenas et al., 2002; Mathet et al., 2003; Lada et al., 2006). This was supported by the observation that coexistence of HBsAg and anti-HBs is correlated with increased nucleotide variability in key areas of the HBV genome (Chen et al., 2011). Current studies also indicated that the serological profile of these patients showed minimal HBV replication and active CHB despite the presence of anti-HBs at a protective level (Colson et al., 2007; Liu et al., 2012). Therefore, we did not investigate the relationship between the HBsAg+/anti-HBs+ serological profiles and HBV replication in this study.

HBeAg positivity can be observed in most patients during the immune-tolerance phase. Transition of the disease to the immune active phase occurs with loss of HBeAgs and the development of anti-HBes in a step called HBeAg seroconversion (McMahon, 2009). Among the 124,865 CHB patients included in this study, 206 (0.2%) were concurrently positive for HBeAg and anti-HBe. Patients in the HBeAg+/anti-HBe+ group were younger as compared to those in the other groups (P < 0.05). Additionally, subgenotype B2 (137, 66.7%) was prevalent in CHB patients concurrently positive for HBeAg and anti-HBe. This genotype has previously been shown to have early and frequent HBeAg seroconversion with less progressive liver disease as compared to genotype C (Chu and Liaw, 2005).
The first immune-tolerance phase is characterized by exceedingly high HBV DNA levels and the presence of HBeAgs. At this time, there is low hepatitis activity, as reflected by normal serum transaminase level despite active HBV replication (Yim and Lok, 2006). When the second immune clearance phase ensues, the liver cells suffer continuous damage due to immune-mediated cytotoxic responses (Liaw et al., 1985; Sprengers et al., 2006). However, following immune attacks, HBV replication is impermanently suppressed. The third low-replication phase is characterized by the absence of HBeAgs, the presence of anti-HBses, persistently normal serum transaminase levels, and low or undetectable serum HBV DNA. HBV could also replicate in the absence of HBeAg, hence the fourth reactivation phase could be observed, which may occur spontaneously (Chu and Liaw, 2007b) or as a result of immunosuppression (Calabrese et al., 2006). In this study, of the 206 patients positive for both HBeAg and anti-HBe, the IC group (42%) was prevalent during the natural phases of CHB. Of the 324 patients positive for both HBsAg and anti-HBs, they were predominantly categorized (39%) into the LR group. The decreased affinity between HBeAg and anti-HBe could explain the concurrent patterns. Furthermore, the concurrent patients may also be undergoing HBeAg and anti-HBe seroconversion.

A limitation to this study was the small number of CHB patients with concurrence of HBs and HBe antigens with their corresponding antibodies. Further large-scale, multi-center studies are needed to clarify the clinical implications of these serological patterns (HBsAg and anti-HBs positivity, or HBsAg and anti-HBs positivity), including specific T cell immune responses, the efficacy of antiviral agents, and the clinical course of the disease.

Conflicts of interest

The authors declare no conflict of interest.

ACKNOWLEDGMENTS

Research supported by the Medical Research Project of Chongqing Health Bureau in 2013 (grant #2013-2-022) and the Science and Technology Research Projects of Chongqing Education Committee in 2016 (grant #KJ1600230).

REFERENCES


HBV infection with concurrence of markers


Genetics and Molecular Research 16 (1): gmr16019102